Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Category: Publications
Home
Publications
11
Nov
2022
Management of adverse events in the AMPECT trial of
nab
-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
0
0
November 11, 2022
November 11, 2022
11
Nov
2022
Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with
nab
-sirolimus, showing durability of response and long-term safety
0
0
November 11, 2022
November 11, 2022
27
Oct
2022
KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor
nab
-Sirolimus Show Improved Antitumor Activity
0
0
October 27, 2022
October 27, 2022
15
Oct
2022
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
0
0
October 15, 2022
October 15, 2022
15
Sep
2022
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
0
0
September 15, 2022
September 15, 2022
05
Jun
2022
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
0
0
June 5, 2022
June 5, 2022
13
Nov
2021
nab
-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program
0
0
November 13, 2021
November 13, 2021
12
Nov
2021
Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of
nab
-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
0
0
November 12, 2021
November 12, 2021
12
Oct
2021
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
0
0
October 12, 2021
October 12, 2021
07
Oct
2021
nab
-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in
PTEN
null bladder cancer (UMUC3) and
TSC2
null liver cancer (SNU398) xenografts
0
0
October 7, 2021
October 7, 2021
Previous
1
2
3
4
5
6
Next